Back to Search Start Over

Advances in Mesenchymal Stem Cell-Derived Exosomes as Drug Delivery Vehicles.

Advances in Mesenchymal Stem Cell-Derived Exosomes as Drug Delivery Vehicles.

Authors :
Rao D
Huang D
Sang C
Zhong T
Zhang Z
Tang Z
Source :
Frontiers in bioengineering and biotechnology [Front Bioeng Biotechnol] 2022 Feb 04; Vol. 9, pp. 797359. Date of Electronic Publication: 2022 Feb 04 (Print Publication: 2021).
Publication Year :
2022

Abstract

Exosomes are tiny vesicles with a double membrane structure that cells produce. They range in diameter from 40 to 150 nm and may contain a variety of biomolecules including proteins and nucleic acids. Exosomes have low toxicity, low immunogenicity, and the ability to encapsulate a wide variety of substances, making them attractive drug delivery vehicles. MSCs secrete large amounts of exosomes and hence serve as an excellent source of exosomes. MSCs-derived exosomes have regenerative and tissue repair functions comparable to MSCs and can circumvent the risks of immune rejection and infection associated with MSC transplantation, indicating that they may be a viable alternative to MSCs' biological functions. In this review, we summarized the drug delivery methods and advantages of exosomes, as well as the advancement of MSC exosomes as drug carriers. The challenges and prospects of using exosomes as drug delivery vectors are presented.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Rao, Huang, Sang, Zhong, Zhang and Tang.)

Details

Language :
English
ISSN :
2296-4185
Volume :
9
Database :
MEDLINE
Journal :
Frontiers in bioengineering and biotechnology
Publication Type :
Academic Journal
Accession number :
35186913
Full Text :
https://doi.org/10.3389/fbioe.2021.797359